Cognition Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Cognition Therapeutics
CGTX Stock  USD 0.45  0.03  7.14%   
Cognition Therapeutics financial statements provide useful quarterly and yearly information to potential Cognition Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cognition Therapeutics financial statements helps investors assess Cognition Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cognition Therapeutics' valuation are summarized below:
Market Capitalization
18 M
Earnings Share
(0.93)
We have found one hundred twenty available fundamental signals for Cognition Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Cognition Therapeutics prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 66.5 M in 2024. Enterprise Value is likely to drop to about 22.7 M in 2024
Check Cognition Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cognition Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 91.2 K, Selling General Administrative of 9.8 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.38. Cognition financial statements analysis is a perfect complement when working with Cognition Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cognition Therapeutics Correlation against competitors.
For more information on how to buy Cognition Stock please use our How to Invest in Cognition Therapeutics guide.

Cognition Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets35 M35.2 M17.4 M
Slightly volatile
Short and Long Term Debt Total165.3 K174 K5.7 M
Slightly volatile
Other Current Liabilities2.6 M4.6 M947.1 K
Slightly volatile
Total Current Liabilities7.2 M10.2 M4.9 M
Slightly volatile
Other Liabilities3.4 M4.4 M2.9 M
Slightly volatile
Property Plant And Equipment Net581.2 K941 K394.3 K
Slightly volatile
Current Deferred Revenue1.5 M1.7 M1.3 M
Very volatile
Accounts Payable3.4 M3.7 M2.7 M
Slightly volatile
Cash29.5 M29.9 M12.7 M
Slightly volatile
Non Current Assets Total962.3 K941 K535.2 K
Slightly volatile
Long Term Debt10.9 M14.8 M8.9 M
Slightly volatile
Cash And Short Term Investments29.5 M29.9 M12.7 M
Slightly volatile
Net Receivables2 M1.3 M3.4 M
Slightly volatile
Common Stock Shares Outstanding27.5 M30 M23.3 M
Slightly volatile
Liabilities And Stockholders Equity35 M35.2 M17.4 M
Slightly volatile
Non Current Liabilities Total494 K520 K46.8 M
Slightly volatile
Inventory2.4 M2.3 M693.5 K
Slightly volatile
Other Current Assets3.2 M3 M595.1 K
Slightly volatile
Total Liabilities10.2 M10.7 M51.5 M
Slightly volatile
Property Plant And Equipment Gross1.5 M2 M1.2 M
Slightly volatile
Total Current Assets34.1 M34.2 M16.9 M
Slightly volatile
Capital Stock18.7 K32 K7.5 K
Slightly volatile
Net Working Capital26.9 M24.1 M12 M
Slightly volatile
Short Term Debt165.3 K174 K177.9 K
Slightly volatile
Common Stock18.7 K32 K7.5 K
Slightly volatile
Property Plant Equipment177.6 K209.7 K264.4 K
Slightly volatile
Common Stock Total Equity23.2 K26.1 K28.4 K
Slightly volatile
Capital Surpluse124.7 M140.2 M152.7 M
Slightly volatile
Short and Long Term Debt471.2 K544 K617.1 K
Slightly volatile
Non Current Liabilities Other1.3 M1.5 M1.7 M
Slightly volatile

Cognition Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization91.2 K96 K9.6 M
Slightly volatile
Selling General Administrative9.8 M13.5 M5.7 M
Slightly volatile
Other Operating Expenses15.3 M25.8 M8.5 M
Slightly volatile
Research Development24.9 M37.2 M17.8 M
Slightly volatile
Cost Of Revenue167 K252 K110.3 K
Slightly volatile
Total Operating Expenses15.3 M25.8 M8.5 M
Slightly volatile
Reconciled Depreciation165.7 K246 K109.8 K
Slightly volatile
Total Other Income Expense Net19 M24.9 M14.8 M
Slightly volatile

Cognition Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation4.1 K4.4 K241.8 K
Slightly volatile
Begin Period Cash Flow23.7 M41.6 M10.8 M
Slightly volatile
Other Cashflows From Financing Activities5.4 M5 M3.7 M
Slightly volatile
Depreciation167 K252 K110.3 K
Slightly volatile
Other Non Cash Items2.4 M2.8 M1.2 M
Slightly volatile
Capital Expenditures109.8 K147 K127 K
Slightly volatile
Change To Operating Activities475.4 K500.4 K829.7 K
Very volatile
Total Cash From Financing Activities4.3 M4.5 M6.8 M
Slightly volatile
End Period Cash Flow29.5 M29.9 M12.7 M
Slightly volatile
Change To Netincome2.6 M4.1 M1.4 M
Slightly volatile
Sale Purchase Of Stock5.6 M6.2 M6.8 M
Slightly volatile
Change Receivables373.6 K420.3 K457.7 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.770.58331.3501
Slightly volatile
Inventory Turnover0.0510.05360.4867
Slightly volatile
Days Of Inventory On Hand7.4 K7 K2.5 K
Slightly volatile
Payables Turnover0.03950.06820.0397
Slightly volatile
Cash Per Share0.840.99790.4858
Slightly volatile
Days Payables Outstanding9.9 K5.4 K10 K
Slightly volatile
Income Quality0.460.62110.6062
Pretty Stable
Current Ratio3.373.36532.7944
Slightly volatile
Graham Number4.363.97414.2256
Pretty Stable
Capex Per Share0.0030.00490.0054
Slightly volatile
Interest Debt Per Share0.02110.02220.292
Slightly volatile
Days Of Payables Outstanding9.9 K5.4 K10 K
Slightly volatile
Ebt Per Ebit0.340.50840.3277
Slightly volatile
Quick Ratio3.33.36532.7405
Slightly volatile
Cash Ratio2.822.94251.8331
Slightly volatile
Days Of Inventory Outstanding7.4 K7 K2.5 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.00921.0409
Very volatile

Cognition Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap66.5 M70 M228 M
Slightly volatile
Enterprise Value22.7 M23.9 M218.8 M
Slightly volatile

Cognition Fundamental Market Drivers

Cash And Short Term Investments29.9 M

Cognition Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cognition Therapeutics Financial Statements

Cognition Therapeutics investors use historical fundamental indicators, such as Cognition Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cognition Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.7 M1.5 M
Cost Of Revenue252 K167 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
AVAVAeroVironment
ELVNEnliven Therapeutics
NFLXNetflix

Additional Tools for Cognition Stock Analysis

When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY